GLP-1 weight loss drugs linked to hair loss risks

Research indicates a potential link between GLP-1 receptor agonists, such as Ozempic and Wegovy, and an increased risk of hair loss, medically known as alopecia. A study led by the University of Pennsylvania and published in ‘The BMJ’ compared users of these medications against patients using SGLT-2 inhibitors and DPP-4 inhibitors, finding evidence that supports clinical observations of hair loss among users.

Possible causes for this side effect include rapid weight loss or biological factors related to hereditary hair loss in men. The exact interaction between the medication, weight loss speed, and individual genetic predisposition remains under investigation.

In a separate development, clinical studies presented at the European Association for the Study of Diabetes annual meeting introduced CBL-514, a new injectable medication. Unlike current treatments that shrink fat cells, CBL-514 triggers apoptosis, causing fat cells to die. Early results suggest it may reduce both subcutaneous and visceral fat, potentially offering benefits for blood pressure and cholesterol levels.